United States — Food and Drug Administration & Oculis

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Oculis will not pursue a filing with for its drug candidate OCS-01, following the failed clinical trials.

Oculis: Oculis is the subject of a securities fraud investigation by multiple law firms after its lead drug candidate, OCS-01, failed to meet primary endpoints in late-stage trials, causing a significant drop in its stock price. The company's decision not to pursue an FDA filing for OCS-01 further negatively impacts its market standing.